Get the Latest MnkD Stock Quote and Information

Author

Reads 295

A Close-Up Shot of a Handwritten Quote
Credit: pexels.com, A Close-Up Shot of a Handwritten Quote

To get the latest MNKD stock quote and information, you can check the company's official website or financial websites like Yahoo Finance or Google Finance. MNKD, also known as Momenta Pharmaceuticals, is a biotechnology company that focuses on developing treatments for rare diseases.

The stock quote can be found on these websites by searching for the company's ticker symbol, MNKD. You can also set up an alert to receive real-time updates on the stock's performance.

MNKD is a publicly traded company listed on the NASDAQ stock exchange, with a market capitalization of over $1 billion. This makes it a significant player in the biotechnology industry.

Take a look at this: S B I Card Share Price

A different take: Cohr Stock Quote

Financial Data

MannKind's revenue is expected to grow significantly, with estimates ranging from $334 million in 2025 to $503 million in 2028. This represents a substantial increase from the $27.86 million in revenue reported in 2018.

The company's sales have been steadily increasing, with a 99.42% change in sales from 2022 to 2023. In 2022, sales were $99.77 million, and in 2023, they reached $198.96 million.

Expand your knowledge: Upcoming Stock Splits 2023

Credit: youtube.com, 🔴 MannKind Corporation MNKD Stock Trading Facts 🔴

Here's a breakdown of MannKind's estimated revenue growth:

The company's operating income has been fluctuating, with a significant decrease of -29.69% from 2022 to 2023. However, it's expected to improve in the future, with estimates suggesting a growth of $193 million in 2028.

Income Statements (USD)

Income Statements (USD) provide a clear picture of a company's financial performance over time. The data can be found in the income statements for the years 2023 to 2017.

Sales have increased dramatically, from 11.75 million USD in 2017 to 198.96 million USD in 2023. The change in sales percentage was 99.42% in 2023. In contrast, the change in sales percentage was -93.28% in 2017.

Gross profit on sales also increased significantly, from -5.48 million USD in 2017 to 136.19 million USD in 2023. The change in gross profit on sales percentage was 222.17% in 2023.

Operating income, however, was negative in 2023, at -10.38 million USD. The change in operating income percentage was not available for 2023.

Income before tax was also negative in 2023, at -10.38 million USD. The change in income before tax percentage was 88.13% in 2023.

Here's a summary of the key changes in income statements over the years:

Balance Sheet in USD

Credit: youtube.com, The BALANCE SHEET for BEGINNERS (Full Example)

The balance sheet is a snapshot of a company's financial situation at a specific point in time. It's a crucial tool for investors, analysts, and business owners to understand the company's financial health.

The total liabilities of the company have been steadily increasing over the years, reaching $721.37 million in 2023.

Looking at the balance sheet total, we can see that it has been growing, but at a slower pace in recent years. The balance sheet total change in percentage has been fluctuating, with a notable increase of 60.93% in 2023.

Here's a breakdown of the balance sheet total change in percentage over the years:

The equity of the company has been decreasing over the years, with a significant drop of 1.74% in 2023.

Company News

MKNK stock has announced a strategic partnership with a leading biotech company to advance the development of a potential treatment for a rare genetic disorder.

This partnership is expected to accelerate the timeline for bringing the treatment to market, with the goal of making it available to patients in the next few years.

The company has also reported positive results from a recent clinical trial, with the treatment showing significant efficacy in reducing symptoms of the disorder.

Corporation Announces Note Exchange

Black and white notebook page with an inspirational quote and eye illustration on a grid background.
Credit: pexels.com, Black and white notebook page with an inspirational quote and eye illustration on a grid background.

MannKind Corporation has just announced a significant debt restructuring through exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2026.

The company will exchange approximately $193.7 million of Notes for 26,749,559 shares of common stock and make a cash payment of $89.2 million to the holders. This transaction reduces MannKind's total outstanding debt by 84%.

MannKind's cash balance will exceed $180 million with approximately 302.5 million shares outstanding after the exchange. The company will save approximately 10.4 million shares of potential dilution and reduce annual interest expense by $4.9 million to $0.9 million.

The exchange will have a substantial impact on MannKind's financial situation, making it a crucial step for the company's growth and development.

On a similar theme: Skanska B Shares

Nintedanib DPI Completes Phase 1 Trial

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases.

The company has announced successful completion of the Phase 1 trial for nintedanib DPI, meeting its primary objective of demonstrating safety and tolerability in healthy volunteers.

Credit: youtube.com, INPULSIS-ON: Nintedanib shows manageable long-term safety for IPF

The trial showed an absence of typical adverse events associated with oral nintedanib, particularly GI and neurologic events.

Only mild, transient adverse events were noted, including cough and a drop in FEV-1, which fully recovered.

The study included single and multiple-ascending doses in adults over 40 years.

MannKind plans to meet with the FDA in the first half of 2025 to discuss late-stage development.

Stock Information

The all-time high MannKind stock closing price was 118.55 on September 23, 2004, and the current 52-week high stock price is 7.63, which is 25.3% above the current share price.

The average MannKind stock price for the last 52 weeks is 5.45, and the 52-week low stock price is 3.17, which is 47.9% below the current share price.

Here are the MannKind historical annual stock price data averages, with the lowest annual % change being -72.20% in 2015:

Stock Price History

MannKind's stock price has had its fair share of ups and downs over the years, with an all-time high closing price of 118.55 on September 23, 2004.

Credit: youtube.com, Using Yahoo Finance to search historical stock price data

The company's 52-week high stock price is 7.63, which is 25.3% above the current share price. This indicates a relatively stable market performance recently.

The 52-week low stock price is 3.17, which is 47.9% below the current share price. This highlights the potential risks associated with investing in MannKind's stock.

The average MannKind stock price for the last 52 weeks is 5.45.

Here's a breakdown of MannKind's historical annual stock price data:

Real Time Quote

The real-time quote is a crucial piece of information for any investor. It tells you the current market price of a stock, which can fluctuate throughout the day.

As of January 28, 2025, the after-market price of the stock is $6.10. This is a decrease of $0.03, or 0.49%, from the previous price.

The Zacks Rank is a short-term rating system that indicates the stock's potential for growth over the next 1 to 3 months. The higher the rank, the better the stock's chances of success.

A unique perspective: Indian Equity Market Timings

Credit: youtube.com, How to fetch real time Stock Prices in Excel using Stock Quote

Here are the Zacks Rank definitions and their corresponding annualized returns:

The Style Scores are a way to identify the best stocks for your personal trading style. They are based on the trading styles of Value, Growth, and Momentum.

The stock has received high scores in all three categories: Value Score A, Growth Score A, Momentum Score A, and VGM Score A.

Frequently Asked Questions

What is the future of MNKD stock?

According to analyst forecasts, MNKD stock is predicted to increase by 27.71% to an average target of 8.71, with estimates ranging from 6.50 to 12. Further analysis of these predictions may provide more insight into the stock's future performance.

What is the projection for MannKind?

According to recent analyst forecasts, MannKind's average price target is $10.00, with a range of $9.00 to $12.00. Check out our latest information for more details on MannKind's future prospects.

What is the valuation of MannKind?

MannKind's valuation is approximately $1.88 billion in market cap and $1.97 billion in enterprise value. Learn more about the company's financials and growth potential.

Is MannKind a good stock to buy?

MannKind has a strong consensus rating of "Buy" among analysts, indicating a positive outlook for the company. If you're considering investing in a medical company, MannKind is worth a closer look.

Vanessa Schmidt

Lead Writer

Vanessa Schmidt is a seasoned writer with a passion for crafting informative and engaging content. With a keen eye for detail and a knack for research, she has established herself as a trusted voice in the world of personal finance. Her expertise has led to the creation of articles on a wide range of topics, including Wells Fargo credit card information, where she provides readers with valuable insights and practical advice.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.